Procyrion Inc., a medical device firm developing the first catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure, has been awarded a $50,000 grant from the National Capital Consortium for Pediatric Device Innovation. The award, part of the FDA Pediatric Device Consortia grant program, presented five innovators with up to $50,000 each to bring their technology projects to life.
Procyrion’s Aortix is a small, continuous-flow pump mounted within a self-expanding anchoring system and delivered via catheter through the femoral artery to the descending thoracic aorta. Once the catheter sheath is pulled back, nickel-titanium anchors deploy to anchor the pump to the aortic wall. Aortix functions by accelerating a portion of the native aortic flow, resulting in reduced work of the heart and increased blood flow to vital organs.